[Recommendations of diagnosis and treatment of primary Sjögren's syndrome in China]
- PMID: 32209192
- DOI: 10.3760/cma.j.cn112138-20200113-00021
[Recommendations of diagnosis and treatment of primary Sjögren's syndrome in China]
Abstract
Sjögren's syndrome is a chronic systemic autoimmune disease characterized by lymphocyte proliferation and progressive exocrine gland damage. In China, standardized diagnosis and treatment for Sjögren's syndrome lags behind other common rheumatic diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Based on the evidence and guidelines from China and other countries, Chinese Sjögren's Syndrome Collaborative Research Group together with stomatologist and ophthalmologist developed Standardization of diagnosis and treatment of primary Sjögren's syndrome. The purposes are: (1) to standardize the detection and interpretation of key indicators for the diagnosis of Sjögren's syndrome, including serum anti SSA antibody and labial gland pathology; (2) to suggest using widely accepted disease activity index in evaluation of the disease; (3) to standardize rational management for Sjögren's syndrome patients with topical and systemic diseases.
干燥综合征(SS)是一种以淋巴细胞增殖和进行性外分泌腺损伤为特征的慢性、系统性自身免疫病。在我国,SS的规范化诊断和治疗落后于其他常见的风湿性疾病,如类风湿关节炎和系统性红斑狼疮。中国医师协会干燥综合征协作组联合口腔科和眼科专家,在借鉴国内外诊治经验和指南的基础上,制定了《原发性干燥综合征诊疗规范》,旨在规范SS诊断中关键指标(如血清抗SSA抗体和唇腺病理学)的检测和解读、建议采用公认的疾病活动度指标评价疾病、规范局部和全身受累患者的合理诊治。.
Keywords: Diagnosis; Primary Sjögren′s syndrome; Treatment.
Similar articles
-
[Recommendations for the diagnosis and treatment of Sjögren's syndrome in China].Zhonghua Nei Ke Za Zhi. 2023 Sep 1;62(9):1059-1067. doi: 10.3760/cma.j.cn112138-20221027-00797. Zhonghua Nei Ke Za Zhi. 2023. PMID: 37650179 Chinese.
-
[The diagnostic value of anti-SSA antibody in primary Sjögren's syndrome].Zhonghua Nei Ke Za Zhi. 2010 May;49(5):410-3. Zhonghua Nei Ke Za Zhi. 2010. PMID: 20646416 Chinese.
-
Sjögren's Syndrome: Oral Manifestations and Treatment, a Dental Perspective.J Dent Hyg. 2015 Dec;89(6):365-71. J Dent Hyg. 2015. PMID: 26684993 Review.
-
Primary Sjögren's syndrome with diffuse cystic lung changes developed systemic lupus erythematosus: a case report and literature review.Oncotarget. 2017 May 23;8(21):35473-35479. doi: 10.18632/oncotarget.16010. Oncotarget. 2017. PMID: 28415674 Free PMC article. Review.
-
Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy.Ann N Y Acad Sci. 2007 Mar;1098:15-21. doi: 10.1196/annals.1384.003. Epub 2007 Mar 1. Ann N Y Acad Sci. 2007. PMID: 17332090 Review.
Cited by
-
Recent Advances of Salivary Gland Biopsy in Sjögren's Syndrome.Front Med (Lausanne). 2022 Jan 10;8:792593. doi: 10.3389/fmed.2021.792593. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35083248 Free PMC article. Review.
-
The titers of antinuclear antibodies are associated with the degree of inflammation and organ damage in Primary Sjögren's Syndrome.Clin Exp Med. 2024 May 8;24(1):96. doi: 10.1007/s10238-024-01357-5. Clin Exp Med. 2024. PMID: 38717644 Free PMC article.
-
Research status and future prospects of extracellular vesicles in primary Sjögren's syndrome.Stem Cell Res Ther. 2022 Jun 3;13(1):230. doi: 10.1186/s13287-022-02912-1. Stem Cell Res Ther. 2022. PMID: 35659085 Free PMC article.
-
miRNA let-7f-5p-encapsulated labial gland MSC-derived EVs ameliorate experimental Sjögren's syndrome by suppressing Th17 cells via targeting RORC/IL-17A signaling axis.J Nanobiotechnology. 2025 Mar 20;23(1):228. doi: 10.1186/s12951-025-03308-y. J Nanobiotechnology. 2025. PMID: 40114173 Free PMC article.
-
Comparison of the effect of iguratimod and hydroxychloroquine on regulatory B cells in the treatment of primary Sjögren's syndrome.Front Med (Lausanne). 2025 Jul 3;12:1573973. doi: 10.3389/fmed.2025.1573973. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40678132 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials